Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.
Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1). Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline. Irrespective of theophylline administration, iNOS antigens were remarkably abundant in ED-1-positive cells on day 5 and 8 post-fenoldopam-infusion (DPI); bFGF antigens were remarkably abundant in ED-1-positive cells on 1 and 3 DPI; TGF-beta1 antigens were observed in ED-1-positive cells on and after 5 DPI. These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen, and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models. On the other hand, TGF-beta1 was not considered to have a suppressive effect on iNOS expression in these models.
Safety Research Laboratories, Yamanouchi Pharmaceutical Co., Ltd., Tokyo, Japan. ikegami@yamanouchi.co.jp
Hisashi
H
Ikegami
Satoru
S
Kajikawa
Kyoko
K
Ito
Aisuke
A
Nii
Hideaki
H
Okamiya
Hiroyuki
H
Nakayama
Kunio
K
Doi
D000284:Administration, Oral; D000818:Animals; D001158:Arteries / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D001167:Arteritis / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D004359:Drug Therapy, Combination; D018818:Fenoldopam / Q000008:administration & dosage / Q000633:toxicity*; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis*; D007150:Immunohistochemistry; D007262:Infusions, Intravenous; D008297:Male; D019001:Nitric Oxide Synthase / Q000096:biosynthesis*; D052247:Nitric Oxide Synthase Type II; D010179:Pancreas / Q000098:blood supply; D051381:Rats; D011916:Rats, Inbred F344; D013806:Theophylline / Q000008:administration & dosage / Q000633:toxicity*; D016212:Transforming Growth Factor beta / Q000096:biosynthesis*; D053773:Transforming Growth Factor beta1; D014665:Vasodilator Agents / Q000633:toxicity*
C508962:Tgfb1 protein, rat; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D014665:Vasodilator Agents; D016222:Fibroblast Growth Factor 2; D013806:Theophylline; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D018818:Fenoldopam